Seres Therapeutics (MCRB) Q3 2025 results reflect a strategic pivot following the September 2024 VOWST Business divestiture, moving operations to a wholly-owned pipeline focused primarily on SER-155.
Financial Performance & Liquidity: The company achieved a massive operational turnaround, reporting Net Income from continuing operations of $21.0M for the nine months ended September 30, 2025, a significant reversal from the \(110.1M loss in the prior year (Basic EPS \)2.41 vs. prior year loss per share). This profitability was aided by a $27.2M gain recognized on the VOWST sale during the
...